Klodjan Stafa is a visionary biomedical research leader with a proven track record of advancing innovation at the intersection of dermatology, neuroscience, and molecular biology. With over 15 years of experience spanning academia and industry, he leads high-impact R&D initiatives that drive product development and business growth on a global scale. Known for his ability to cultivate top-performing teams and foster strategic partnerships, Klodjan combines scientific depth with business acumen to deliver breakthrough solutions. His work has contributed to multi-million dollar product launches, influential publications, and patented technologies, positioning him as a trusted voice in translational science and a catalyst for meaningful change in biomedical research.

Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.